Increased 18F-deoxyglucose uptake in the lung during the first weeks of radiotherapy is correlated with subsequent Radiation-Induced Lung Toxicity (RILT): A prospective pilot study

Radiotherapy and Oncology

Volumn 91, Issue 3, 2009, Pages 415-420

  Ruysscher, Dirk De ^a   Houben, Ans ^b   Aerts, Hugo J W L ^b   Dehing, Cary ^b   Wanders, Rinus ^b   Öllers, Michel ^b   Dingemans, Anne Marie C ^a   Hochstenbag, Monique ^a   Boersma, Liesbeth ^b   Borger, Jacques ^b   Dekker, Andre ^b   Lambin, Philippe ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRO CLINIC   (Netherlands)

Author keywords

Lung; NSCLC; Radiopneumonitis; Radiotherapy; RILT; Toxicity

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG UPTAKE; DYSPNEA; FEMALE; HUMAN; HUMAN TISSUE; LUNG; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; MULTIPLE CYCLE TREATMENT; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RADIATION DOSE;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIATION INJURIES; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 65749120006     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.01.004     Document Type: Article

References (40)

1. Rosenzweig K.E., Mychalczak B., Fuks Z., et al. Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer. Cancer J 6 (2000) 82-87
2. Hayman J.A., Martel M.K., Ten Haken R.K., et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy update of a phase I trial. J Clin Oncol 19 (2001) 127-136
3. Narayan S., Henning G.T., Ten Haken R.K., et al. Results following treatment to doses of 92.4 or 102.9 Gy on a phase I dose escalation study for non-small cell lung cancer. Lung Cancer 44 (2004) 79-88
4. Socinski M.A., Morris D.E., Halle J.S., et al. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer. A dose-escalation phase I trial. J Clin Oncol 22 (2004) 4341-4350
5. Rosenman J.G., Halle J.S., Socinski M.A., et al. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys 54 (2002) 348-356
6. Kong F.M., Ten Haken R.K., Schipper M.J., et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 63 (2005) 324-333
7. Bradley J., Graham M.V., Winter K., et al. Toxicity and outcome results of RTOG 9311. A phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 61 (2005) 318-328
8. Thirion P., Holmberg O., Collins C.D., et al. Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy. Radiother Oncol 71 (2004) 163-166
9. Belderbos J., Heemsbergen W., De Jaeger K., et al. Final results of a phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 66 (2006) 126-134
10. C. Saunders MI, Rojas A, Lyn BE et al. Dose-escalation with CHARTWEL (Continuous Hyperfractionated Accelerated Radiotherapy Week-End Less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer. Clin Oncol 2002;14:352-60.
11. D. Rojas AM, Lyn BE, Wilson EM et al. Toxicity and outcome of a phase II trial of taxane-based neoadjuvant chemotherapy and 3-dimensional, conformal, accelerated radiotherapy in locally advanced nonsmall cell lung cancer. Cancer 2006;107:1321-30.
12. van Baardwijk A., Bosmans G., Boersma L., et al. Individualized radical radiotherapy of non-small-cell lung cancer based on normal tissue dose constraints: a feasibility study. Int J Radiat Oncol Biol Phys 71 (2008) 1103-1110
13. De Ruysscher D., Wanders R., van Haren E., et al. HI-CHART: a phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys 71 (2008) 132-138
14. Martel M.K., Ten Haken R.K., Hazuka M.B., et al. Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis. Int J Rad Oncol Biol Phys 3 (1994) 575-581
15. Graham M., Purdy J., Emami B., et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Rad Oncol Biol Phys 45 (1999) 323-329
16. Robnett T.J., Machtay M., Vines E.F., et al. Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. Int J Rad Oncol Biol Phys 48 (2000) 89-94
17. Rancati T., Ceresoli G.L., Gagliardi G., et al. Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. Radiother Oncol 67 (2003) 275-283
18. Roach III M., Gandara D., Yuo H., et al. Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol 13 (1995) 2606-2612
19. Hernando M.L., Marks L.B., Bentel G.C., et al. Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Rad Oncol Biol Phys 51 (2001) 650-659
20. Kwa S., Lebesque J., Theuws J., et al. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Rad Oncol Biol Phys 42 (1998) 1-9
21. Yorke E.D., Jackson A., Rosenzweig K.E., et al. Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Rad Oncol Biol Phys 54 (2002) 329-339
22. Claude L., Perol D., Ginestet C., et al. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis. Radiother Oncol 71 (2004) 175-181
23. Kim T.H., Cho K.H., Pyo H.R., et al. Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer. Radiology 235 (2005) 208-215
24. Kong F.M., Pan C., Eisbruch A., et al. Physical models and simpler dosimetric descriptors of radiation late toxicity. Semin Radiat Oncol 17 (2007) 108-120
25. De Jaeger K., Seppenwoolde Y., Kampinga H.H., et al. Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 58 (2004) 1378-1387
26. Zhao L., Sheldon K., Chen M., et al. The predictive role of plasma TGF-beta1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer. Lung Cancer 59 (2008) 232-239
27. Arpin D., Perol D., Blay J.Y., et al. Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitis. J Clin Oncol 23 (2005) 8748-8756
28. Hartsell W.F., Scott C.B., Dundas G.S., et al. Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03. Am J Clin Oncol 30 (2007) 368-376
29. Gaugler M.H., Vereycken-Holler V., Squiban C., et al. Pravastatin limits endothelial activation after irradiation and decreases the resulting inflammatory and thrombotic responses. Radiat Res 163 (2005) 479-487
30. Williams J.P., Hernady E., Johnston C.J., et al. Effect of administration of lovastatin on the development of late pulmonary effects after whole-lung irradiation in a murine model. Radiat Res 161 (2004) 560-567
31. Zhang M., Qian J., Xing X., et al. Inhibition of the tumor necrosis factor-alpha pathway is radioprotective for the lung. Clin Cancer Res 14 (2008) 1868-1876
32. ICRU Report 50. Prescribing, recording, and reporting photon beam therapy. international commission on radiation units and measurements. Oxford, UK: Oxford University Press; 1993.
33. Nijsten S.M., Mijnheer B.J., Dekker A.L., et al. Routine individualised patient dosimetry using electronic portal imaging devices. Radiother Oncol 83 (2007) 65-75
34. Senan S., De Ruysscher D., Giraud P., et al. On behalf of the Radiotherapy Group of the European Organization for Research and Treatment of Cancer (EORTC). Literature-based recommendations for treatment planning and execution for high-precision radiotherapy in lung cancer. Radiother Oncol 71 (2004) 139-146
35. Hicks R.J., Mac Manus M.P., Matthews J.P., et al. Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys 60 (2004) 412-418
36. Kong F.M., Frey K.A., Quint L.E., et al. A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. J Clin Oncol 25 (2007) 3116-3123
37. Chen H., Cowan M.J., Hasday J.D., et al. Tobacco smoking inhibits expression of proinflammatory cytokines and activation of IL-1R-associated kinase, p38, and NF-kappaB in alveolar macrophages stimulated with TLR2 and TLR4 agonists. J Immunol 179 (2007) 6097-6106
38. Hart J.P., McCurdy M.R., Ezhil M., et al. Radiation pneumonitis: correlation of toxicity with pulmonary metabolic radiation response. Int J Radiat Oncol Biol Phys 71 (2008) 967-971
39. Kong F.M., Ao X., Wang L., et al. The use of blood biomarkers to predict radiation lung toxicity: a potential strategy to individualize thoracic radiation therapy. Cancer Control 15 (2008) 140-150
40. De Ruysscher D., Botterweck A., Dirx M., Pijls-Johannesma M., Wanders R., Hochstenbag M., Dingemans A.C., Bootsma G., Geraedts W., Simons J., Pitz C., and Lambin P. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol 20 (2009) 98-102